Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by VBL Therapeutics
VBL Therapeutics Announces Results of Annual and Special Original
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its shareholders voted to approve the previously announced proposed merger (the “Merger”) with Notable Labs, Inc.
VBL Therapeutics Reminds Shareholders to Vote in the Original
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annual and special meeting (the “Meeting”) for shareholders of record as of September 5, 2023.
VBL Therapeutics Announces that S-4 Registration Statement Original
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its registration statement on Form S-4 in connection with the proposed merger with Notable Labs, Inc. (“Notable”) has been declared effective by the U.S. Securities and Exchange Commission (“SEC”).
VBL Therapeutics Reports Second Quarter 2023 Financial Original
Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash equivalents as of June 30, 2023 MODI’IN, Israel and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.
VBL Therapeutics Reports First Quarter 2023 Financial Original
MODI’IN, Israel and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update. “During the first quarter, we made continued progress in the steps we are taking to maximize shareholder value and are focused on closing the announced merger with Notable Labs, as expeditiously as possible,” said Prof. Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics.
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable’s proprietary Predictive Precision Medicines Platform (“PPMP”) Notable’s validated PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient’s cancer treatment and predict their clinical response to the actual treatment Notable has applied its PPMP to selecting and developing two clinical-stage...
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
Read full article MODIIN, Israel and NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced today that it has entered into an agreement to monetize its manufacturing facility in Modiin, Israel and certain related assets, for $7.1 million in cash. VBL also has the right to sell certain equipment excluded from the agreement for additional cash consideration.
VBL Therapeutics Reports Third Quarter 2022 Financial Original
TEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Press release content from Globe Newswire. The AP news staff was not involved in its creation. TEL AVIV, Israel and NEW YORK, Sept.
VBL Therapeutics Announces Second Quarter 2022 Financial Original
TEL AVIV, Israel and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Original
TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced top-line data from the Phase 3 OVAL clinical trial of ofra-vec (ofranergene obadenovec; VB-111) in platinum-resistant ovarian cancer.
VBL Therapeutics Announces Appointment of Sam Backenroth as
Amos Ron to Retire as CFO and Will Continue to Serve as Corporate Secretary, Advisor to VBL October 05, 2021 08:00 ET | Source: VBL Therapeutics VBL Therapeutics Or Yehuda, ISRAEL TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately.
VBL Presents New Data on MOSPD2 Antibodies as Potential Treatment for NASH and Colitis at DDW
May 06, 2020 07:00 ET | Source: VBL Therapeutics Study was rated in the top 10% of all abstracts in this category and was selected as Poster of Distinction Data demonstrate the potential of VBL's proprietary MOSPD2 mAbs for chronic inflammatory indications, via a novel and distinct mechanism targeting monocyte migration TEL AVIV, Israel, May 06, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), (the “Company”) today announced new data implicating the potential of its anti-MOSPD2...
VBL Therapeutics Announces Second Quarter 2017 Financial Results
TEL AVIV, Israel, Aug. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced financial results for the three and six months ended June 30, 2017 and provided a corporate update. “VBL made significant advances on clinical and operational fronts during the second quarter of 2017,” said Prof. Dror Harats, Chief Executive Officer of VBL Therapeutics. “We continue to progress in our Phase 3 GLOBE study investigating our lead asset VB-111 in patients with recurrent glioblastoma (rGBM).
VBL Therapeutics Announces First Quarter 2017 Financial Results
TEL AVIV, Israel, May 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, announced financial results for the first quarter ended March 31, 2017, as well as a corporate update.
Identification of Motile Sperm Domain-Containing Protein 2 as Regulator of Human Monocyte Migration
AbstractBinding of chemokines to their cognate receptors on monocytes instigates a cascade of events that directs these cells to migrate to sites of inflammation and cancerous tissues. Although targeting of selected chemokine receptors on monocytes exhibited preclinical efficacy, attempts to translate these studies to the clinic have failed thus far, possibly due to redundancy of the target receptor.
Identification of Motile Sperm Domain-Containing Protein 2 as Regulator of Human Monocyte Migration
Identification of Motile Sperm Domain–Containing Protein 2 as Regulator of Human Monocyte Migration Itzhak Mendel, Niva Yacov, Yaniv Salem, Oshrat Propheta-Meiran, Eti Ishai, Eyal Breitbart The Journal of Immunology January 30, 2017, 1601662; DOI: 10.4049/jimmunol.1601662
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with VBL
Contact VBL, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack